McKESSON CORPORATION (MCK) FY2027 Q1 P&L / Income Statement

McKESSON CORPORATION (MCK) FY2027 Q1 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

105,380,000,000 US dollars

Cost of sales

101,695,000,000 US dollars

Gross profit

3,685,000,000 US dollars

Total operating expenses

2,366,000,000 US dollars

Operating income

1,319,000,000 US dollars

Other income (expense), net (calculated)

negative 11,000,000 US dollars

Income before income taxes

1,308,000,000 US dollars

Income tax expense

276,000,000 US dollars

Net income

1,032,000,000 US dollars

North American Pharmaceutical

86,773,000,000 US dollars

Oncology & Multispecialty

14,222,000,000 US dollars

Prescription Technology Solutions

1,566,000,000 US dollars

Medical-Surgical Solutions

2,819,000,000 US dollars

Selling, distribution, general, and administrative expenses

2,264,000,000 US dollars

Claims and litigation charges, net

negative 34,000,000 US dollars

Restructuring, impairment, and related charges, net

136,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to McKESSON CORPORATION: $614.00 M; to noncontrolling interests: $418.00 M.